NASDAQ:SYRE Spyre Therapeutics (SYRE) Stock Price, News & Analysis $25.76 +1.97 (+8.28%) (As of 07/3/2024 ET) Add Compare Share Share Today's Range$23.49▼$26.1850-Day Range$22.71▼$39.2952-Week Range$8.43▼$47.97Volume535,310 shsAverage Volume1.09 million shsMarket Capitalization$1.04 billionP/E RatioN/ADividend YieldN/APrice Target$43.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestTrends Get Spyre Therapeutics alerts: Email Address Spyre Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside67.6% Upside$43.17 Price TargetShort InterestBearish10.76% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.05Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.82) to ($3.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.80 out of 5 starsMedical Sector811th out of 896 stocksPharmaceutical Preparations Industry384th out of 424 stocks 3.5 Analyst's Opinion Consensus RatingSpyre Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSpyre Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Spyre Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.76% of the float of Spyre Therapeutics has been sold short.Short Interest Ratio / Days to CoverSpyre Therapeutics has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in Spyre Therapeutics has recently increased by 5.68%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSpyre Therapeutics does not currently pay a dividend.Dividend GrowthSpyre Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SYRE. Previous Next 2.3 News and Social Media Coverage News SentimentSpyre Therapeutics has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Spyre Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for SYRE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Spyre Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.20% of the stock of Spyre Therapeutics is held by insiders.Percentage Held by Institutions80.39% of the stock of Spyre Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Spyre Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Spyre Therapeutics are expected to decrease in the coming year, from ($3.82) to ($3.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spyre Therapeutics is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spyre Therapeutics is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Spyre Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestDOLLAR RECALL ON THE AGENDAHave you heard about Executive Order 14067? This lesser-known order introduced the Digital Dollar, an alarming plan aimed at controlling your spending. And it gets even more concerning: in November, the Federal Government and banks initiated a test program to implement the Digital Dollar.Click here to receive your complimentary Wealth Management Guide >> About Spyre Therapeutics Stock (NASDAQ:SYRE)Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.Read More SYRE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SYRE Stock News HeadlinesJune 18, 2024 | prnewswire.comSpyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel DiseaseJune 3, 2024 | prnewswire.comSpyre Therapeutics Announces Grants of Inducement AwardsJuly 5, 2024 | Golden Crest (Ad)Urgent: Safeguard Your Finances from Biden NOWHave you heard about Executive Order 14067? This lesser-known order introduced the Digital Dollar, an alarming plan aimed at controlling your spending. And it gets even more concerning: in November, the Federal Government and banks initiated a test program to implement the Digital Dollar.May 29, 2024 | prnewswire.comSpyre Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 15, 2024 | prnewswire.comSpyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of DirectorsMay 14, 2024 | markets.businessinsider.comPositive Outlook on Spyre Therapeutics’ IBD Pipeline and Financial StabilityMay 10, 2024 | markets.businessinsider.comSpyre Therapeutics: Strong Buy Recommendation on Robust Pipeline and Financial StabilityMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed: Spyre Therapeutics’ Promising Pipeline and Expert Team Drive Positive OutlookJuly 5, 2024 | Golden Crest (Ad)Urgent: Safeguard Your Finances from Biden NOWHave you heard about Executive Order 14067? This lesser-known order introduced the Digital Dollar, an alarming plan aimed at controlling your spending. And it gets even more concerning: in November, the Federal Government and banks initiated a test program to implement the Digital Dollar.May 10, 2024 | finanznachrichten.deSpyre Therapeutics, Inc.: Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 10, 2024 | investorplace.comSYRE Stock Earnings: Spyre Therapeutics Misses EPS for Q1 2024May 9, 2024 | chron.comSpyre Therapeutics: Q1 Earnings SnapshotMay 9, 2024 | prnewswire.comSpyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 3, 2024 | prnewswire.comSpyre Therapeutics Announces Grants of Inducement AwardsMay 3, 2024 | msn.comBaird Initiates Coverage of Spyre Therapeutics (SYRE) with Outperform RecommendationMay 3, 2024 | msn.comCarvana upgraded, Block downgraded: Wall Street's top analyst callsApril 20, 2024 | investing.comSpyre Therapeutics Inc (SYRE)April 17, 2024 | msn.comSpyre Therapeutics (SYRE) Price Target Increased by 5.00% to 42.84April 5, 2024 | markets.businessinsider.comBuy Rating Affirmed for Spyre Therapeutics on Promising mAb Dosing and Market PositioningApril 1, 2024 | prnewswire.comSpyre Therapeutics Announces Grants of Inducement AwardsMarch 25, 2024 | markets.businessinsider.comStrong Buy Rating for Spyre Therapeutics Based on Promising SPY001 Data and Financial PositionMarch 20, 2024 | investing.comSpyre Therapeutics secures $180 million in PIPE dealMarch 18, 2024 | markets.businessinsider.comSpyre Therapeutics Privately Places $180 Mln Of Shares; Stock Up In Pre-MarketMarch 18, 2024 | msn.comSpyre Therapeutics climbs 5%, prices $180M private financingMarch 18, 2024 | prnewswire.comSpyre Therapeutics Announces $180 Million Private PlacementMarch 6, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Humana (HUM), Alnylam Pharma (ALNY) and Spyre Therapeutics (SYRE)March 4, 2024 | msn.comHere's What Could Help Spyre Therapeutics (SYRE) Maintain Its Recent Price StrengthSee More Headlines Receive SYRE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spyre Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/04/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SYRE Previous SymbolNASDAQ:SYRE CUSIPN/A CIK1636282 Webwww.aeglea.com Phone512-942-2935Fax512-872-5121Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$43.17 High Stock Price Target$54.00 Low Stock Price Target$31.00 Potential Upside/Downside+67.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($71.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-338,790,000.00 Net MarginsN/A Pretax Margin-52,933.57% Return on EquityN/A Return on Assets-79.05% Debt Debt-to-Equity RatioN/A Current Ratio11.38 Quick Ratio11.38 Sales & Book Value Annual Sales$890,000.00 Price / Sales1,165.86 Cash FlowN/A Price / Cash FlowN/A Book Value($0.22) per share Price / Book-117.09Miscellaneous Outstanding Shares40,280,000Free Float37,785,000Market Cap$1.04 billion OptionableOptionable Beta2.94 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Cameron Turtle DPHIL (Age 34)Ph.D., CEO & Director Comp: $674.17kMr. Scott L. Burrows (Age 47)Chief Financial Officer Comp: $331.81kMs. Heidy Abreu King-Jones J.D. (Age 41)L.L.M., Chief Legal Officer & Corporate Secretary Comp: $568.87kDr. Janet Gunzner-Toste M.B.A.Ph.D., Senior Vice President of OperationsMr. Brian ConnollyChief Technical OfficerMr. Eric McIntyreVice President of Finance & Investor RelationsMr. James MyersVice President of Quality & ComplianceDr. Kelly Boothe Ph.D.Senior Director of Corporate Communications & Investor RelationsDr. Justin LaFountaine Ph.D.Senior Vice President of Corporate DevelopmentMs. Melissa CooperSenior Vice President of PeopleMore ExecutivesKey CompetitorsAxsome TherapeuticsNASDAQ:AXSMAvidity BiosciencesNASDAQ:RNACrinetics PharmaceuticalsNASDAQ:CRNXPerrigoNYSE:PRGOPrestige Consumer HealthcareNYSE:PBHView All Competitors SYRE Stock Analysis - Frequently Asked Questions Should I buy or sell Spyre Therapeutics stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Spyre Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SYRE shares. View SYRE analyst ratings or view top-rated stocks. What is Spyre Therapeutics' stock price target for 2024? 8 brokers have issued 12 month target prices for Spyre Therapeutics' stock. Their SYRE share price targets range from $31.00 to $54.00. On average, they anticipate the company's share price to reach $43.17 in the next twelve months. This suggests a possible upside of 67.6% from the stock's current price. View analysts price targets for SYRE or view top-rated stocks among Wall Street analysts. How have SYRE shares performed in 2024? Spyre Therapeutics' stock was trading at $21.52 at the start of the year. Since then, SYRE shares have increased by 19.7% and is now trading at $25.76. View the best growth stocks for 2024 here. When is Spyre Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our SYRE earnings forecast. How were Spyre Therapeutics' earnings last quarter? Spyre Therapeutics, Inc. (NASDAQ:SYRE) posted its earnings results on Monday, May, 13th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by $0.30. How do I buy shares of Spyre Therapeutics? Shares of SYRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SYRE) was last updated on 7/5/2024 by MarketBeat.com Staff From Our PartnersUrgent Alert: Is the U.S. Implementing a Digital Dollar?Our exclusive guide, "Exploring the Future of the U.S. Dollar in a Digital World," is your essential resource ...Gold Gate Capital | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredDOLLAR RECALL ON THE AGENDAHave you heard about Executive Order 14067? This lesser-known order introduced the Digital Dollar, an alarming...Golden Crest | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.